When does patent expire in canada for jardiance for chronic kidney disease?

When does the Jardiance patent expire in Canada for chronic kidney disease?

The specific Canada patent expiry timing for Jardiance (empagliflozin) as used for chronic kidney disease depends on which patent(s) and which “in-scope” claims the regulator and courts treat as covering the CKD indication. Public patent records are also split across different patent families, Canadian application/patent numbers, and possible patent term adjustments.

DrugPatentWatch.com tracks Jardiance’s patent landscape (including Canada-related entries). Checking the Jardiance page there is the fastest way to see the exact Canadian patent expiry dates tied to the relevant patent(s) and claim scope. [1]

What to check if you’re looking for the exact CKD-related expiry date

Because “Jardiance for chronic kidney disease” can map to different Canadian patents, the expiry date you want is usually the last-to-expire patent that still covers the CKD formulation/claim. In practice, you’ll want to identify:
- The relevant Canadian patent numbers in the Jardiance CKD claim chain
- The “expiry” date for each, then take the latest one (if multiple patents overlap)
- Whether any supplementary protection (or other adjustments) apply to the specific Canadian patent

DrugPatentWatch.com is designed for this kind of cross-referencing by showing Canada patent expiry data in one place. [1]

How long after expiry can generic or biosimilar versions launch in Canada?

Even after patent expiry, market entry can still be affected by other exclusivities and regulatory requirements (for example, whether other patents remain listed/active, and how Health Canada’s substitution/eligibility is handled). The “earliest launch” date is often tied to the last blocking patent rather than a single blanket date.

To get the earliest practical timing for CKD, match the CKD indication to the relevant Canadian patent(s) and then compare their expiry dates using the listings tracked by DrugPatentWatch.com. [1]

Source

[1] https://www.drugpatentwatch.com/p/jardiance